partnering

Strategy: Flexible win-win partnerships

Areas of partnership
TechnoVax brings product expertise and initial R&D funding
Partner provides necessary resources to advance candidate through clinical POC

Whether through strategic alliances, licensing arrangements and/or research collaborations, our approach is based on a flexible, creative methodology designed to establish mutually beneficial relationships that are positioned to capture upside potential beyond what either partner could achieve individually.

TechnoVax has partnered with a leading player in the field of pulmonary drug delivery to develop shelf-stable, self- inhaled powder VLP vaccines for flu and RSV. Currently there is no such product on the market for respiratory vaccination, and the need is critical.

Our portfolio of vaccine candidates has a potential addressable market of over $5 billion in annual worldwide sales.